A. Marozsan

发表

Influences on Trimerization and Aggregation of Soluble, Cleaved HIV-1 SOSIP Envelope Glycoprotein

John P. Moore, I. Wilson, A. Ward, 2013, Journal of Virology.

Multifaceted Mechanisms of HIV Inhibition and Resistance to CCR5 Inhibitors PSC-RANTES and Maraviroc

E. Arts, A. Marozsan, D. Dudley, 2013, Antimicrobial Agents and Chemotherapy.

Natural Variation in the V3 Crown of Human Immunodeficiency Virus Type 1 Affects Replicative Fitness and Entry Inhibitor Sensitivity

E. Arts, A. Marozsan, M. Lobritz, 2007, Journal of Virology.

HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.

John P. Moore, T. Ketas, A. Marozsan, 2007, Virology.

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

John P. Moore, C. Herrera, A. Marozsan, 2005, Virology.

Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9

John P. Moore, I. Wilson, C. D. Murin, 2013, Proceedings of the National Academy of Sciences.

Anti – HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140 , a CCR 5 Monoclonal Antibody

N. Stambler, M. Saag, A. Marozsan, 2010 .

Targeting Complement Pathways During Cold Ischemia and Reperfusion Prevents Delayed Graft Function

A. Marozsan, K. Bouchard, J. Xu, 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

A yeast recombination-based cloning system to produce chimeric HIV-1 viruses and express HIV-1 genes.

Yong Gao, E. Arts, A. Marozsan, 2005, Methods in molecular biology.

Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy.

M. Ruseva, Zhao-Xue Yu, A. Marozsan, 2016, Journal of the American Society of Nephrology : JASN.

Ef fi cacy of Targeted Complement Inhibition in Experimental C 3 Glomerulopathy

M. Ruseva, Zhao-Xue Yu, A. Marozsan, 2015 .

ENPP1 enzyme replacement therapy improves blood pressure and cardiovascular function in a mouse model of generalized arterial calcification of infancy

A. Marozsan, Tayeba Khan, Sylvia Vong, 2018, Disease Models & Mechanisms.

Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies

John P. Moore, T. Ketas, Helen J Kim, 2014, Retrovirology.

Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action

Zhao-Xue Yu, D. Sheridan, A. Marozsan, 2018, PloS one.

Partial Enzymatic Deglycosylation Preserves the Structure of Cleaved Recombinant HIV-1 Envelope Glycoprotein Trimers*

John P. Moore, I. Wilson, A. Ward, 2012, The Journal of Biological Chemistry.

Succession in the Gut Microbiome following Antibiotic and Antibody Therapies for Clostridium difficile

Jun Zhu, Frederic D. Bushman, William C. Olson, 2012, PloS one.

Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen

M. Lederman, D. Kuritzkes, Heather A Baird, 2005, AIDS research and therapy.

Mechanisms Involved in Stimulation of Human Immunodeficiency Virus Type 1 Replication by Aminooxypentane RANTES

E. Arts, R. Offord, D. Templeton, 2001, Journal of Virology.

Relationships between Infectious Titer, Capsid Protein Levels, and Reverse Transcriptase Activities of Diverse Human Immunodeficiency Virus Type 1 Isolates

Eric J. Arts, Heather A Baird, E. Arts, 2004, Journal of Virology.

The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.

B. Korber, John P. Moore, Steven Wolinsky, 2004, Virology.

In Vitro Intersubtype Recombinants of Human Immunodeficiency Virus Type 1: Comparison to Recent and Circulating In Vivo Recombinant Forms

Eric J. Arts, Yong Gao, E. Arts, 2002, Journal of Virology.

A Dual Infection/Competition Assay Shows a Correlation between Ex Vivo Human Immunodeficiency Virus Type 1 Fitness and Disease Progression

E. Arts, G. Vanham, A. Marozsan, 2000, Journal of Virology.

Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans

Ryan McBride, Robyn L. Stanfield, Andrew B. Ward, 2013, PLoS pathogens.

HIV-1 SOSIP envelope glycoprotein 2

John P. Moore, I. Wilson, A. Ward, 2013 .

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

Yan Liu, William R. Schief, Ryan McBride, 2011, Science.

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120

Yan Liu, Ryan McBride, Robyn L. Stanfield, 2013, Nature Structural &Molecular Biology.

Differences in the Fitness of Two Diverse Wild-Type Human Immunodeficiency Virus Type 1 Isolates Are Related to the Efficiency of Cell Binding and Entry

E. Arts, A. Marozsan, J. Reeves, 2005, Journal of Virology.

The Cambrian Conundrum: Early Divergence and Later Ecological Success in the Early History of Animals

John P. Moore, D. Burton, Chi‐Huey Wong, 2011 .

Comparing the Ex Vivo Fitness of CCR5-Tropic Human Immunodeficiency Virus Type 1 Isolates of Subtypes B and C

Heather A Baird, E. Arts, A. Blauvelt, 2003, Journal of Virology.

Design and preclinical characterization of ALXN1210: A next generation anti-C5 monoclonal antibody with improved pharmacokinetics and duration of action

Zhao-Xue Yu, D. Sheridan, A. Marozsan, 2016 .

Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures

Sriram Subramaniam, Mario J. Borgnia, William C. Olson, 2011, Proceedings of the National Academy of Sciences.

Variable Sensitivity of CCR5-Tropic Human Immunodeficiency Virus Type 1 Isolates to Inhibition by RANTES Analogs

E. Arts, R. Offord, A. Marozsan, 2000, Journal of virology.

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.

N. Stambler, M. Saag, A. Marozsan, 2010, The Journal of infectious diseases.

Escape of HIV-1 from a Small Molecule CCR5 Inhibitor Is Not Associated with a Fitness Loss

John P. Moore, E. Arts, C. Anastassopoulou, 2007, PLoS pathogens.

Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates.

E. Arts, A. Marozsan, 2003, Journal of virological methods.

Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies

John P. Moore, I. Wilson, T. Ketas, 2014, Retrovirology.

Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

C. Fichtenbaum, N. Stambler, M. Saag, 2010, Antimicrobial Agents and Chemotherapy.

Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.

B. Kennedy, A. Marozsan, Paul J Maddon, 2012, The Journal of infectious diseases.

Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses.

John P. Moore, Steven Wolinsky, K. Kunstman, 2004, Virology.

Clonal Analysis of HIV-1 Co-receptor Tropism Change Following Treatment with PRO 140, a CCR5 Monoclonal Antibody

A. Marozsan, 2008 .

Influences on Trimerization and Aggregation of Soluble, Cleaved HIV-1 SOSIP Envelope Glycoprotein

John P. Moore, I. Wilson, A. Ward, 2013, Journal of Virology.

Erwin Success in the Early History of Animals The Cambrian Conundrum : Early Divergence and Later Ecological

John P. Moore, D. Burton, Chi‐Huey Wong, 2011 .